Thiotepa, Cyclophosphamide, Clarithromycin and Cytarabine

Exclusion Criteria

• •1\. Have a history of cancer and have received any treatment for this tumor in the past 3 years, except for superficial bladder cancer, basal cell or squamous cell carcinoma of the skin, cervical intraepithelial carcinoma (CIN), or prostate epithelium Internal carcinogenesis (PIN); 2. Known to be serologically positive for HIV, active hepatitis B, active hepatitis C virus or syphilis; 3. Suffering from mental illness or other conditions and unable to cooperate with the requirements of research treatment and monitoring; 4. Pregnant patients or patients who cannot take appropriate contraceptive measures during treatment; 5. Received hematopoietic stem cell transplantation within the past 1 year; 6. Active heart disease, defined as one or more of the following:
• •1. Have a history of uncontrolled or symptomatic angina;
• •2. Myocardial infarction less than 6 months from study enrollment;
• •3. Have a history of arrhythmia that requires drug treatment or has severe clinical symptoms;
• •4. Uncontrolled or symptomatic congestive heart failure (\>NYHA class 2);
• •5. The ejection fraction is lower than the lower limit of the normal range. 7. Patients who meet the following criteria:
• •<!-- -->
• •1. Major surgery (except diagnostic surgery) is planned within 4 weeks before enrollment or during the study period, or the surgical wound has not fully healed before enrollment;
• •2. Those who have received (attenuated) live vaccines within 4 weeks before enrollment;
• •3. Patients with suspected active or latent tuberculosis;
• •4. Participate in other clinical trials one month before enrollment 8. Those who the researcher believes are not suitable for enrollment